Sibylla

Sibylla Biotech Appoints Sonia Poli as Chief Scientific Officer

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Partnership, Knowledge, Tau, Drug development, CSO, CNRS, AC, Pharmacy, Entrepreneurship, Therapy, Eli Lilly, Cyclin D1, Protein, Research fellow, Drug discovery, Sibylla, Fine chemical

Sibylla Biotech today announces the appointment of Sonia Poli, Ph.D., as Chief Scientific Officer (CSO).

Key Points: 
  • Sibylla Biotech today announces the appointment of Sonia Poli, Ph.D., as Chief Scientific Officer (CSO).
  • As a seasoned pharmaceutical R&D executive, Dr. Poli has held various leadership and executive positions at both large and small pharmaceutical companies across disciplines and indications.
  • Dr. Poli will guide the scientific direction and strategy at Sibylla as the company advances its proprietary pipeline of small molecule Folding Interfering Degraders (FIDs) to address a range of therapeutic areas.
  • This blend of expertise has already generated and validated several compounds that act on proteins of oncological interest," said Dr. Sonia Poli, CSO of Sibylla Biotech.

Sibylla Biotech Appoints Dominique Bridon as Executive Chairman of the Board

Retrieved on: 
Thursday, September 28, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Drug development, University, Therapy, Doctor of Philosophy, Organic chemistry, Berkeley, EpiVax, CSO, Ipsen, Protein folding, Innovation, Sibylla, University of Clermont-Ferrand, OMICS Publishing Group, Patent, École Nationale Supérieure Agronomique de Toulouse, Cancer, Drug discovery, Entrepreneurship, Chemical engineering, Cyclin D1, Pharmaceutical industry

Sibylla Biotech today announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors.

Key Points: 
  • Sibylla Biotech today announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors.
  • Dr. Bridon brings more than 30 years of experience in operations as well as research and development in the pharmaceutical and biotechnology sectors.
  • As an expert in implementing AI-based technologies for drug development and with a broad knowledge base in precision oncology, Dr. Bridon has successfully led drug discovery efforts from conception to clinical development.
  • Joining Sibylla, Dr. Bridon will contribute his expertise and lead the Board as Sibylla expands its proprietary pipeline of innovative protein degraders.

Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform

Retrieved on: 
Tuesday, October 4, 2022
Biotechnology, Professional Services, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Science, Clinical Trials, Finance, Entrepreneurship, Doctor of Philosophy, Physics, Sibylla, Technology, Biotechnology, National Institute, Protein folding, Intermediate, Protein, University of Trento, University of Perugia, Trento, Cyclin D1, Cancer, Nikos Vertis, University, FIDS, Therapy, Fine chemical

We have gained the support of a strong group of expert investors and the capital to advance our small molecule pipeline, expand our protein folding simulation technology platform and bring additional expertise to our team.

Key Points: 
  • We have gained the support of a strong group of expert investors and the capital to advance our small molecule pipeline, expand our protein folding simulation technology platform and bring additional expertise to our team.
  • Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein.
  • Through their protein folding simulation technology platform, Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state.
  • Vertis SGR funded the breakthrough discovery technology resulting from the collaboration, enabling the initial validation of Sibyllas technology.